

- Ti, L.K., 414
 Tirilomis, T., 211
 Tobias, J.D., 306
 Toker, A., 721
 Torri, G., 647
 Toumbouras, M., 143
 Trehan, N., 22, 452
 Tse, J., 486
 Tugrul, M., 613, 721
 Turjanmaa, V.M.H., 199
- Ulusoy, H.B., 465
 Unnikrishnan, M., 740
 Uysal, S., 768
- Vaage, J., 314, 598
 Valeske, K., 617
 van der Linden, J., 329
 van der Linden, P., 747
 van Dijk, D., 396
 van Pelt, F., 357
 Vaporciyan, A.A., 131
 Vartuli, G.M., 204
- Venuta, F., 29
 Vezina, D.P., 134
 Vidne, B.A., 691
 Virmani, S., 281
 Vlachtsis, H., 226
 Vohra, A., 226
 Vuylsteke, A., 783
- Wajima, Z., 430
 Wallin, M., 470
 Walters, G.K., 694
 Wartier, D.C., 709
 Warren, S.M., 51
 Weightman, W., 728
 Weisenberg, M., 321
 Weiss, H.R., 486
 Welsby, I.J., 403
 Weng, Y.-S., 585
 White, W.D., 45
 Whiteheart, D.L., 725
 Winnerkvist, A., 598
 Wood, R.K. Jr., 699
 Woodcock, B., 359
- Wright, S., 141
 Wu, Z.-K., 459
- Xénitos, P., 142
- Yalçın, Y., 686
 Yamaura, K., 703
 Yan, L., 486
 Yanulevich, J., 524
 Yavru, A., 613
 Yazigi, A., 782
 Yndgaard, S., 36
 Yoganathan, T., 604
- Zabeeda, D., 40, 321
 Zaugg, M., 747
 Zehr, K.J., 447
 Zhao, X., 193
 Zhou, S.X., 585
 Zilmer, K., 314
 Zilmer, M., 314
 Zollinger, A., 217
 Zvara, D.A., 252

SUBJECT INDEX

- ACAS (Asymptomatic Carotid Atherosclerosis Study), 10
 Acetylcholine, 318
 Acetylcysteine, 317
 Adenosine, myocardial tissue oxygen pressure during canine coronary artery constriction and, 495–498
 Adhesive agents, tissue, 106–107, 112
 α_2 -adrenoceptor agonists, 580
 Age(ing)
 acute normovolemic hemodilution and, 750
 anesthesia for a nonagenarian and, 647–654
 cardiovascular
 arrhythmias and, 520–521
 background for, 512
 beta-receptor stimulation response changes and, 513, 515–516
 congestive heart failure and, 520
 connective tissue stiffening and, 513–515
 hemodynamic instability during anesthesia and, 518–519
 increased systemic vascular resistance and, 516
 inherent instability and, 517–518
 perioperative myocardial ischemia and, 519–520
 perioperative stroke and, 521
 sympathetic nervous system activity and, 516–517
 vagal activity changes and, 517
 effects of, 648–653
 Airway
 abnormalities of, wire-guided Arndt blocker for one-lung ventilation with, 352–354
 central, obstruction of, bronchoscopic procedures for, anesthetic considerations with, 638–646
 laryngeal mask, deep intravenous sedation with propofol and, trans-esophageal echocardiography and, 443–446
 trauma to
 double-lumen tube insertion and, 295
 incidence of, 321
 upper, edema of, 726–727
 Albumin, 598, 602–603
- Alfentanil, remifentanil *versus*, hemodynamic response during day-case rigid bronchoscopy and, 336–340
 Allograft, 240
 Allopurinol, 317
 Alveolar dead space, calculation of, 208–209
 Alzheimer's disease, 343
 American College of Cardiology/American Heart Association Guidelines on Perioperative Evaluation before Noncardiac Surgery, stress testing and, 694–698
 American Society of Anesthesiologists and Society of Cardiovascular Anesthesiologists report on observer variation in trans-esophageal echocardiography, 438–439
 Amplatzer septal occluder, 755–756, 758–762
 atrial septal defect sizing and, 759
 Analgesia
 epidural
 coronary artery bypass graft surgery and, 151–153, 154–159
 single-lung transplantation and, 36–39
 thoracic
 lung volume reduction surgery and, 359–360
 remifentanil for one-lung ventilation and, 69–71
 severe emphysema and, 373–374
 Anastomosis, devices for, 101–102
 sutureless, 405–406
 Ancrod, 632–633, 633–634
 Ancure endografting system (Endovascular Technologies graft), 661
 Anesthesia
 general, 85
 cerebrovascular morbidity and mortality post carotid endarterectomy and, 14–15
 high epidural with, combined off-pump coronary artery and aortic aneurysm surgery and, 226–229
 intraoperative echocardiography during ventricular assist device insertion and, 113
 operations without, 160
 opioid, 51, 60–68, 465 (*See also* specific agents)

Anesthesia (*Continued*)

- regional
 - bupivacaine toxicity with, emergent cardiopulmonary bypass and, 357–358
 - cerebrovascular morbidity and mortality post carotid endarterectomy and, 15
 - epidural
 - lung transplantation and, 34
 - thoracic
 - high, multiple-graft, off-pump coronary artery bypass graft surgery and, 160–164
 - meperidine for, arterial oxygenation during one-lung ventilation and, 302–305
 - redo off-pump coronary artery bypass graft surgery and, 84–86
 - thiopental *versus* propofol for, implantation of automatic internal cardioverter-defibrillator using, 613–616
 - thoracic epidural, redo coronary artery bypass graft surgery bridge using, 629–631
 - volatile, hypoxic pulmonary vasoconstriction and, 73–75
- Anesthesiology team, off-pump coronary artery bypass graft surgery and, 108
- Anesthetic management, 232–235
- aorticaval fistula and, 236–239
 - atrial septal occluder device and, 757–758
 - balanced regimen, lung transplantation and, 31–34
 - cardiac catheterization and, pediatric, 683–684
 - goal with, 691
 - propofol-ketamine mixture and, 691–693
 - propofol *versus* ketamine for, 686–690
 - cardiovascular aging effects on, 512–523
 - central airway obstruction relief and, 639
 - anesthetic choice for, 640
 - anesthetic emergence and, 640
 - anesthetic induction for, 639–640
 - premedication for, 639
 - deep intravenous, transesophageal echocardiography and, 443–446
 - early extubation criteria and, 33–34
 - elective cardiac surgery in a nonagenarian and, 647–654
 - gas mixture for, ventilation mode during cardiopulmonary bypass and, 40
 - hemodynamic instability during, 518–519
 - inhalation, malignant hyperthermia and, 625–628
 - intraoperative, severe emphysema and, 376
 - juvenile nasopharyngeal antituberculosis resection and, 622–624
 - Klippel-Feil syndrome and, 502–505
 - lung transplantation and, 36–39
 - lung volume reduction surgery and, 359–360
 - nonhypotensive patients under, systolic blood pressure variations in, 188–192
 - patent ductus arteriosus with other cardiac defects and, 740–743
 - repair of Ebstein's anomaly and, 232–235
 - severe emphysema and, 373–374
 - uncomplicated patent ductus arteriosus and, 742
 - ventricular assist device insertion in infants and children and, 617–621

AneuRx graft, 661–662

Aneurysm Detection and Management (ADAM) Trial, 659–660

Aneurysm(s)

- aortic
 - abdominal
 - endovascular repair of, perioperative morbidity and mortality effects of
 - background for, 655, 659

Aneurysm(s) (*Continued*)

- intraoperative management and, 656
- open *versus* endoluminal, 661–664
- study group size and, 655–656
- technological advances and, 656
- repair of
 - endovascular
 - indications for, 659–660
 - perioperative morbidity and mortality effects of, 655–658, 659–667
 - open *versus* endovascular, 655–657
 - comparative studies of, 663–664
 - cost-effectiveness of, 664
 - durability of, 662–663
 - perioperative mortality of, 661–662
 - randomized controlled trials of, 659–660
 - surgery for, off-pump coronary artery bypass graft surgery and, anesthesia for, 226–229
- complications of, aorticaval fistula as, anesthetic management of, 236–239
- repair of, biochemical markers of cerebrospinal ischemia after, 598–603

Angina

- refractory, 258
- warmup, 519
- Angina pectoris, unstable, 91
- Angina With Extremely Serious Operative Mortality Evaluation (AWESOME) study, 265–266
- Angiofibroma, nasopharyngeal, juvenile, resection of, anesthetic management of, 622–624

Angioplasty

- coronary artery bypass graft surgery *versus*, 263–268, 397
 - background for, 263–264
 - history of, 264
 - multivessel disease and, 264–266
 - single-vessel disease and, 266–267
- failed percutaneous transluminal coronary, effect on myocardial diastolic function of intracoronary vasodilators and, 604–612

Antioxidant(s), protective effects of, 314–320

Antithrombin, 171–175

Antithrombin III, 173

Aorta

- anastomotic device for, 101–102
- aneurysm of, biochemical markers of cerebrospinal ischemia after, 598–603
- ascending, intra-aortic balloon placed via, intraoperative transesophageal echocardiographic imaging of, 736–739
- dissection of, deep hypothermic circulatory arrest for, Cesarean section, preeclampsia and, 252–257
- root replacement of, transesophageal echocardiography used to diagnose valvular pathology during, 271–272
- stenosis of, frozen mediastinum and, surgical approach with, 770–772
- surgery of, retrograde cerebral perfusion during, 768–769

Aortic valve. *See* Valve, aortic

Aprotinin, aortic dissection repair and, 252–257

Argatroban, 633

Argentine Randomized Trial of Coronary Angioplasty *vs.* Bypass Surgery (ERACI II), 264

Arndt Endobronchial Blocker System, 79–81, 352–354, 727

Arrhythmia(s)

- cardiovascular aging and, 520–521
- Ebstein's anomaly and, 234

- Arrhythmia(s) (*Continued*)
 fenoldopam mesylate and, 20
 ischemic-reperfusion-induced, 459–464
 off-pump coronary artery bypass graft surgery and, antiarrhythmic effect of regional ischemic preconditioning with, 459–464
 postoperative, 459
 supraventricular, perioperative, lung resection and, 378
 ventricular, 462
- Arterial Revascularization Therapies Study, 264
- Artery
 carotid
 diameter of, 15
 endarterectomy of (*See* Endarterectomy)
 coronary
 disease of, treatment in 2003 of, 258–259
 percutaneous interventions with, 258
 internal mammary, 263
 left subclavian, stenosis of, vertebral-subclavian steal due to, 773–774
 pulmonary, catheter placement in, pressure waveform during, 129–130
 stiffening of, 513–514
- Aspiration, 362
- Aspirin
 preoperative use of, 180
 protamine-induced pulmonary vasoconstriction and, 309–313
- Assist device(s)
 biventricular, transesophageal echocardiography during insertion of, 113
 left ventricular (LVAD), insertion of
 intraoperative echocardiography during, 113
 unplanned, coronary artery bypass graft surgery and, 499–501
 ventricular, anesthetic considerations in infants and children receiving, 617–621
- Asymmetry of information, 563
- Asymptomatic Carotid Atherosclerosis Study (ACAS), 10, 13
- Atrial septal defect, 233
 occlusion devices for closing of, 755–763
 sizing of, Amplatzer Septal occluder and, 759
- Atrium
 left, isoflurane effects in dogs with pacing-induced cardiomyopathy and, 709–714
 right
 thrombus of, mental status changes due to, 509–511
 in vitro effect of remifentanyl and fentanyl on, 465–469
- Autograft, pulmonary, 240
- AWESOME (Angina With Extremely Serious Operative Mortality Evaluation) study, 265–266
- Balloon dilation, 644
- BARI (Bypass Angiographic Revascularization Investigation), 264
- Baroreflex system, cardiovascular aging and, 516
- Beating Heart Against Cardioplegic Arrest Studies, 396
- Beating-heart surgery. *See* Coronary artery bypass graft (CABG) surgery, off-pump (OPCAB)
- Beta-adrenergic responses, triiodothyronine treatment effects on, stunned cardiac myocytes and, 486–490
- Beta-blocker(s), perioperative myocardial infarction and, 95
- Beta-receptor stimulation, changes in response with age to, 513, 515–516
- Bias, observer, transesophageal echocardiography and, 430–442
- Biocor SJM valve, 243
- Bioprosthesis. *See* Xenograft
- Bispectral index, cerebral hypoperfusion detection using, 76–78, 506–508
- Bivalirudin, 632–635
- Bleeding
 heparin-coated extracorporeal circuits and, 165–170
 off-pump coronary artery bypass graft surgery and, with and without cardiopulmonary bypass during, 447–451
- Blood
 autologous, preoperative donation of (PAD)
 background for, 121, 126
 clinical effectiveness of, 126
 cost-effectiveness of, 127
 costs of, 123
 economic evaluations of, 123, 124
 emerging transfusion-transmitted infectious diseases and, 121–122
 health effects of, 121
 immune-mediated adverse events and, 122
 immune-mediated complications and, 122
 limitations of, 122–123
 patient anxiety and, 122
 safety of, 126–127
 transfusion-transmitted viral infections and, 121
 harvesting of, acute normovolemic hemodilution and, 751
- Blood-brain barrier, 2
- Blood flow
 multialveolar compartment lung modeling of left-right distribution of, 209
 variations in, regional venous oxygenation and systemic inflammatory response and, 182–187
- Blood pressure
 cardiovascular aging and, 516
 lability of, general anesthesia and, 519
 systolic, variations in anesthetized nonhypotensive patients, 188–192
- Blood products, predictors of use during cardiopulmonary bypass of, 176–181
- Brachytherapy, 642–643
- Brain, retrograde cerebral perfusion and, 764–765
- Brain injury, surrogates for, 1–2
- Bronchiole, 364
- BronchoCath double-lumen tube, 289, 300, 301
- Bronchoscopy
 central airway obstruction relief with, 638–646
 anesthetic choice for, 640
 anesthetic emergence and, 640
 anesthetic induction for, 639–640
 balloon dilation for, 644
 brachytherapy for, 642–643
 complication with, 640–641
 cryotherapy for, 644
 electrocautery for, 644
 neodymium:yttrium-aluminum-garnet laser for, 642
 photodynamic therapy for, 643–644
 premedication for, 639
 preoperative evaluation for, 638–639
 pulmonary function analysis in, 638–639
 radiologic studies in, 638
 stenting for, 641–642
 ventilation method for, 640
 fiberoptic, 639–640, 642, 643–644
 rigid, day-case, opioid supplementation for, 336–340
- Bronchospasm, 374

- Bupivacaine, 357–358, 630
- Bypass Angioplasty Revascularization Investigation (BARI), 264, 590
- Cannula, malposition in a hepatic vein of, 269–270
- Carbon dioxide
de-airing of cardiothoracic wound cavity model with, 329–335
end-tidal *versus* transcutaneous monitoring techniques during one-lung ventilation using, 306–308
- Cardiac output
anesthetized humans and, 747
awake humans and, 747
continuous measurements of
comparison of, 211–216
post-cardiopulmonary bypass
thermodilution for
continuous, and whole-body impedance cardiography for, 199–203
Doppler methods *versus*, 193–198
inert gas throughflow *versus*, 204–210
measurement of, transesophageal Doppler device for, 217–220
- Cardiography, whole-body impedance, cardiac output monitoring with, 199–203
- Cardiomyopathy, pacing-induced, canine, 709–714
- Cardioplegia
antegrade, 766 (*See also* Cerebral perfusion, retrograde)
pyruvate-fortified, 715–720
- Cardiopulmonary bypass (CPB)
bivalirudin use during, heparin-induced thrombocytopenia and, 632–635
blood product use during, predictors of, 176–181
cardiac output measurement after (*See* Cardiac output)
complication of, 40
emergent, bupivacaine cardiotoxicity and, 357–358
heparin-coated *versus* uncoated extracorporeal circuit use during, 165–170
heparin resistance during, anticoagulation strategies and, 171–175
high-frequency ventilation of lungs on postbypass oxygenation *versus* other ventilation methods during, 40–44
lung injury and, 40–43
mitral valve replacement surgery with, malignant hyperthermia development during, 625–628
pulmonary endothelial function after, antioxidant protective effects on, 314–320
pyruvate-enhanced cardioprotection during, 715–720
regional oxygenation and systemic inflammatory response during, temperature and blood flow variation effects on, 182–187
renal dysfunction potential with, 17
renal protective effect of fenoldopam during, 491–494
risk factors during off-pump coronary artery bypass graft surgery leading to emergency use of, 452–458
systemic inflammatory response during, 260
tepid, 182, 184
- Cardiopulmonary function, assessment of, 372
- CardioQ, thermodilution cardiac output *versus*, off-pump coronary artery surgery and, 728–732
- Cardiovascular Anesthesiologists Society and American Society of Anesthesiologists report, observer variation in transesophageal echocardiography and, 438–439
- Cardioverter-defibrillator, automatic internal, implantation of, thiopental *versus* propofol for, 613–616
- Catheterization, cardiac, pediatric
anesthetic management of, 683–684
propofol-ketamine mixture and, 691–693
- Catheterization, cardiac, pediatric (*Continued*)
propofol *versus* ketamine and, 686–690
- Catheter(s)
endhole balloon wedge pressure, 80
Fogarty embolectomy, 80
Fogarty occlusion, 352–354
triple-lumen, defective, 361–363
- Cefazolin, prophylactic use in children of, 221–225
- Central nervous system
acute normovolemic hemodilution and, 750
damage to, biochemical markers of, 598
- Cerebral perfusion, retrograde
brain perfusion during, 764–765
cerebral embolization risk and, 765–766
cerebral metabolic demand and, 765
clinical experience with, 766–767
deep hypothermic circulatory arrest and, 764–767
neuroprotection in thoracic aortic surgery using, 768–769
- Cerebrospinal fluid, biochemical markers of, repair of aortic aneurysms and, 598–603
- Cesarean section, aortic dissection and, aprotinin during deep hypothermic circulatory arrest during, 252–257
- Child(ren). *See also* Infant(s); Neonate(s)
juvenile nasopharyngeal angiofibroma resection in, anesthetic considerations for, 622–624
prophylactic use of cefazolin in, 221–225
prophylactic use of gentamicin in, 221–225
ventricular assist device insertion in, anesthetic considerations for, 617–621
- Chronic obstructive pulmonary disease (COPD), 364
ventilator-associated pneumonia and, 27
- Chylothorax, postpneumonectomy, tension hydrothorax due to, 131–133
- Circuit, extracorporeal, heparin-coated *versus* uncoated, 165–170
- Circulatory arrest, deep hypothermic
aortic dissection during pregnancy and, aprotinin use during, 252–257
retrograde cerebral perfusion for, 764–767
- Coagulation, acute normovolemic hemodilution effects on, 750–751
- Cognitive dysfunction. *See* Neurologic complications
- Collagen, 513
- Color kinesis, left ventricular regional wall motion analysis during abdominal aortic cross-clamping with, 703–708
- Comorbid disease, 512
- Conduit, left ventricular apico-aortic, 770–772
- Congenital heart disease
cardiac catheterization for, propofol *versus* ketamine for, 683–684, 686–690
incidence of, 691
- Connective tissue stiffening, cardiovascular aging and, 513–514
- Continuous positive airway pressure (CPAP), extubation and, 34
- Contour analysis, continuous pulse, continuous pulmonary artery thermodilution technique *versus*, 211–216
- COPD (chronic obstructive pulmonary disease), 364
- Coronary artery bypass graft (CABG) surgery
anastomotic devices for, 101–112
aortic (proximal), 101–102
background of, 101
discussion of, 107–112
distal, 102–107
automated interrupted suturing device for, 103, 111
nitinol U-clip as, 102–103, 111
one-shot device as, 103–105, 111
Symmetry Bypass Aortic Connector as, 107

- Coronary artery bypass graft (CABG) surgery (*Continued*)
 tissue adhesives as, 106–107, 112
 VCS Autosuture Device as, 106
 Ventrica magnetic vascular positioner as, 107
 limitations of, 111–112
 angioplasty *versus*, 263–268
 background for, 263–264
 asymmetric cerebral near-infrared oximetric measurements during, 773–774
 emergency
 elective *versus*, risk profiles, outcomes, and resource requirements with, 594–597
 preoperative predictors of, 596–597
 epidural analgesia and, 151–153, 154–159
 frequency of, 500
 general surgery *versus*, difficult laryngoscopy with, 321–324
 glucose-insulin-potassium influence on growth hormone/insulin-like growth factor axis during, 470–477
 heparin-coated *versus* -uncoated extracorporeal circuits in patients undergoing, 165–170
 myocardial lactate metabolism as functional status marker after, 478–485
 neurocognitive decline after, nicotine and, 341–345
 off-pump (OPCAB), 258, 396
 anesthesiology team and, 108
 antiarrhythmic effect of regional, 459–464, 456
 aortic aneurysm surgery with, anesthesia for, 226–229
 benefits of, 396
 ambiguity of, 397
 evidence for, 396–397
 CardioQ and thermodilution cardiac output measurement during, 728–732
 complications associated with, 89
 contraindications to, 398
 conventional bypass surgery *versus*, 397–398
 coronary angioplasty *versus*, 397
 gender influence on resource utilization and, 346–351
 hemodynamic instability during, risk factors leading to, 452–458
 multiple-graft, high thoracic epidural anesthesia only for, advantages and disadvantages of, 162–163
 redo, high thoracic epidural anesthesia only for, 84–86
 right ventricular rupture during, 87–89
 systemic air embolism during, 403–404
 unplanned left ventricular assist device insertion after, 499–501
 with and without cardiopulmonary bypass for, bleeding and transfusion comparisons, 447–451
 off-pump (OPCAB) *versus*, 397–398
 costs of, 261
 credentialing and training residents and, 262
 hemodynamic factors and, 261
 learning curve and, 262
 morbidity and mortality and, 261
 neurologic events and, 260–261
 perioperative course and, 261
 quality of life and, 261
 reinterventions and, 261
 systemic inflammatory response role in, 260
 redo, thoracic epidural anesthesia as bridge to, 629–631
 robotically assisted, 258
 short- and long-term survival after, risk factors affecting, gender and, 585–593
 Coronary Artery Surgery Study (CASS), 91, 266, 589–590
 Cost-benefit analysis, 123
 Cost-effectiveness analysis, 123
 Cost-utility analysis, 123
 Creutzfeldt-Jakob disease, 122
 Cricoid, adult, tracheobronchial tree diameter *versus*, double-lumen tube selection and, 299–301
 Cross-clamping, aortic
 myocardial blood flow effects of, 706
 quantitative analysis of left ventricular regional wall motion with color kinesis during, 703–708
 Cryolife-O'Brien valve, 243
 Cryotherapy, 644
 Cyanosis, pediatric, propofol anesthesia and, 689
 Danaparoid, 633
 Decision analysis, 123
 Deep hypothermic circulatory arrest. *See* Circulatory arrest, deep hypothermic
 Defibrillation, threshold testing of, thiopental *versus* propofol for sedation during, 613–616
 Desflurane
 myocardial tissue oxygen pressure during canine coronary artery constriction and, 495–498
 one-lung ventilation and, 73–75
 Dexmedetomidine, propofol-based sedation regimens *versus* regimens based on, coronary artery bypass graft surgery and, 576–584
 Diabetes mellitus, difficult laryngoscopy in patients with, coronary artery bypass graft surgery *versus* general surgery and, 321–323
 Diastolic dysfunction, 608–609
 Diastolic function, effect of intracoronary vasodilators on, failed percutaneous transluminal coronary angioplasty and, 604–612
 Digoxin, 521
 Diltiazem, 95
 Dipyridamole thallium stress test, 703–708
 Diverticulum, tracheal, one-lung ventilation and, 355–356
 Dobutamine stress echocardiography, 695–696, 697–698
 Dopamine, 17
 Doppler imaging
 tissue and, 608
 transesophageal, 217–220
 Dutch Randomised Endovascular Aneurysm Management (DREAM) trial, 664
 Dyspnea, post pneumonectomy, 131–133
 Ebstein's anomaly
 anomalies associated with, 233
 repair of, anesthetic management for, 232–235
 Echocardiography
 dobutamine stress, 695–696, 697–698
 epicardial and epiaortic, 422–429
 advantages of, 428
 background for, 422
 disadvantages of, 428
 imaging planes for, 423
 midesophageal aortic valve short-axis equivalent view with, 423
 proximal aortic arch equivalent view with, 426
 results with, 427–428
 right ventricular outflow tract view with, 425–426
 short- and long-axis equivalent views of the ascending aorta, 416
 transgastric basal short-axis equivalent view with, 423
 transgastric 2-chamber equivalent view with, 424–425
 transgastric long-axis equivalent view with, 424
 transgastric mid-short-axis equivalent view with, 423–424

- Echocardiography (*Continued*)
 transesophageal (*See* Transesophageal echocardiography)
- Ectopy, ventricular, 521
- Edema
 pulmonary
 post-lung resection, 378
 postpneumonectomy, 388–395
 upper airway, 726–727
- Edwards Prima Plus valve, 243
- Effusion, pericardial, respiratory variation and, 45–50
- Elastin, 513
- Electrocautery, 644
- Embolism, air, 331
 systemic, off-pump coronary artery bypass graft surgery and, 403–404
- Embolization, cerebral, risk of, retrograde cerebral perfusion and, 765–766
- Emphysema, severe, 364–387
 anatomy of, 364
 anesthesia and analgesia with, 373–374
 induction of, 374–376
 arrhythmias with, 378
 barotrauma and, 377–378
 dynamic pulmonary hyperinflation with, 376–377
 lung transplantation for, 370–371
 lung volume reduction surgery for, 366–370
 medical treatment of, 366
 monitoring of, 373
 physiology of, 364–366
 positive end-expiratory pressure and, 376–377
 post-lung resection pulmonary edema and, 378
 preoperative evaluation with, 371–372
 pulmonary hypertension with, 378
 right ventricular dysfunction with, 378
 sedation with, 373
- Enderectomy, carotid
 asymptomatic carotid stenosis treatment with, 13–16
 perioperative mortality and morbidity and, factors affecting, 10–16
 rate of, increases in, 15–16
- Endhole balloon wedge pressure catheter, 80
- Endobronchial blocker(s)
 one-lung ventilation and, 636–637
 pediatric, 79–81
 single-lumen endotracheal tube with, double-lumen tube *versus*, 725–727
- Endocarditis, surgical intervention for, findings suggestive of, 135
- Endoleak, 662–663
- Endothelium
 coronary blood flow regulation and, 610–611
 protective effect of antioxidants after cardiopulmonary bypass on, 314–320
- Endovascular Technologies (Ancure endografting system) graft, 661
- Enolase, neuron-specific, 1–3, 4–9, 598, 601–603
- Enteral feeding, ventilator-associated pneumonia and, 27
- Enzyme(s), spillage in brain of, brain injury markers and, 1–2
- ERACI II (Argentine Randomized Trial of Coronary Angioplasty *vs.* Bypass Surgery), 264
- Etidocaine, 357
- Euro-Collins solution, modified, theophylline added to, hypothermic preservation of lung and, 721–724
- EXCLUDER endograft, 662
- Extubation, early adaptive support ventilation and, 571–575
 anesthetic technique and, 33–34
 lung transplantation and, 29–35
- Extubation, early adaptive support ventilation and (*Continued*)
 evaluative criteria and, 29
 optimal remifentanil dosing regimen and, 58
 remifentanil with general anesthesia and, 69–71
 single-lung transplantation and, 36–39
 timing of, 29
- Fast-track surgery, 29, 31–34
 adaptive support ventilation and, 571–575
- Fenoldopam
 low-dose, renal dysfunction and, 17–21
 renal protective effects of, cardiopulmonary bypass and, 491–494
- Fentanyl, in vitro effect on isolated human right atria and saphenous veins of, 465–469
- Fibrillation, atrial, post off-pump coronary artery bypass graft surgery, 459
- Fibrosa, pseudoaneurysm of mitral-aortic intervalvular, 668–671
- Fick principle, 204, 207–208
- Fick's law, 333
- Fingerprint, metabolic, 483
- Fistula
 aortocaval, 236–239, 234
 bronchopleural, differential lung airway pressure release ventilation and, 744–746
 venous, bronchopulmonary, 403–404
- Fogarty embolectomy catheter, 80
- Frank-Starling relationship, 513
- Gas, inert, throughflow method, 204–210
- Gender
 coronary artery bypass graft surgery and, short- and long-term survival after, 585–593
 female (*See also* Women)
 cerebrovascular morbidity and mortality post carotid endarterectomy and, 14–15
 influence on resource utilization of, off-pump coronary artery bypass graft surgery and, 346–351
 perioperative mortality and morbidity post carotid endarterectomy and, 10–16
- Gentamicin, prophylactic use in children of, 221–225
- Glial fibrillary acidic protein, 598, 601–603
- Glucose-insulin-potassium, influence on growth hormone/insulin-like growth factor axis during coronary artery bypass graft (CABG) surgery of, 470–477
- Glutathione, 318
- Glycoprotein IIb/IIIa antagonists, 171–175
- Glycosylation, 513
- Growth hormone/insulin-like growth factor axis, glucose-insulin-potassium influence on, coronary artery bypass graft (CABG) surgery and, 470–477
- Guidelines for Perioperative Cardiovascular Evaluation for Noncardiac Surgery, stress testing and, 694–698
- Heart failure, congestive, volume status and, 520
- Heartflo automated anastomotic device, 103
- Hematoma, epidural, 154
- Hemodialysis, indwelling central venous catheter for, mental status changes due to right atrial thrombus caused by, 509–511
- Hemodilution, acute normovolemic, 747–754
 avoidance of allogeneic blood transfusion and, 751
 basic principles of, 747
 blood harvesting and, 751
 cardiovascular physiology during, 747–748

- Hemodilution, acute normovolemic (*Continued*)
 central nervous system and, 750
 compensatory mechanisms for, anesthesia for, 748
 costs of, 751
 critical hemoglobin of whole organism, and, 748–749
 effects on coagulation of, 750–751
 elderly patients and, 750
 heart disease and, 749–750
 indications for, 751
 intraoperative period and, 751–752
 outlook for, 752
 postoperative period and, 752
 splanchnic organs and, 750
- Hemodynamic changes
 coronary artery bypass graft surgery *versus* off-pump coronary artery
 bypass graft surgery and, 261
 instability in, anesthesia and, 518–519
 one-lung ventilation and, remifentanil effects during, 73–75
 remifentanil efficacy and safety and, 60–68
 remifentanil optimal dosing regimen and, 51–59
 risk factors during off-pump coronary artery bypass graft surgery
 leading to, 452–458
- Hemoglobin, critical levels of, acute normovolemic hemodilution lev-
 els of, 748–749
- Hemoglobinuria, 8–9
- Hemolysis
 neuron-specific enolase serum concentrations and, 8–9
 S-100 β serum concentrations and, 8–9
- Hemolytic reaction, acute, 122
- HemoSonic100, 217, 219–220
- Hemothorax, postpneumonectomy, management of, 389–390
- Heparin
 -protamine complex, 311
 resistance during cardiopulmonary bypass to, anticoagulation strat-
 egies for, 171–175
 reversal of, bleeding and transfusions with, coronary artery bypass
 graft surgery with and without cardiopulmonary bypass
 and, 447–451
- Hepatitis viruses, non-A-E, 122
- Heterograft. *See* Xenograft
- Hirudin(s), recombinant, 633
- Histamine, release of, 468
- Holter monitor, 94
- Homograft, 240
- Hydrothorax, tension, postpneumonectomy chylothorax and, 131–133
- Hypercholesterolemia, 91
- Hypercoagulability, 91
- Hyperinflation, dynamic pulmonary, 364
- Hypertension
 pulmonary
 adverse outcomes after orthotopic liver transplantation and, 699–
 702
 post-lung resection, 378–379
 remifentanil hydrochloride and, 66–67
- Hyperthermia, malignant, development during mitral valve replace-
 ment surgery of, 625–628
- Hypoperfusion, cerebral, bispectral index detection of, 76–78
- Hypoplasia, pulmonary, long-segment right, ventricular septal defect
 and patent ductus arteriosus and, anesthetic manage-
 ment of, 740–743
- Hypotension
 cardiovascular aging and, 519
 defective triple-lumen catheter and, 361–363
- Hypotension (*Continued*)
 intraoperative, adverse outcomes after orthotopic liver transplanta-
 tion and, 699–702
 post intravenous morphine, 468
 propofol and, 576
 remifentanil hydrochloride and, 67–68
- Hypothermia, 180
- Hypovolemia, 88
- Hypoxemia, one-lung ventilation and, 294
- Immunosuppression, 122
 ventilator-associated pneumonia and, 27
- Infant(s). *See also* Child(ren); Neonate(s)
 ventricular assist device insertion in, anesthetic considerations for,
 617–621
- Infarction, cerebral, 509
- Inflammatory response, systemic, 260
 cardiopulmonary bypass and, 260
 temperature and blood flow variation effects on, 182–187
- Insufflation device, de-airing of cardiothoracic wound cavity model
 with, 329–335
- Insulin-like growth factor/growth hormone axis, Influence of glucose-
 insulin-potassium on, coronary artery bypass graft
 (CABG) surgery and, 470–477
- Intensive care unit
 economic benefit of organizational restructuring of, 565–570
 intensivist-run, 563–564
 optimal remifentanil dosing regimen and patient time in, 55
 sedation after coronary artery bypass graft surgery and, 576–584
- Intensivist, intensive care unit run by, 563–564
- Intermittent positive-pressure ventilation (IPPV), 22
 ventilator-associated pneumonia and, 27
- Intra-aortic balloon pump. *See* Pump, intra-aortic balloon
- Intubation
 endotracheal, risks of, 162
 tracheal, duration of, off-pump coronary artery bypass graft surgery
 and, 346–351
- Ischemia
 cerebral, bispectral index detection of, 77–78
 cerebrospinal, biochemical markers of, aneurysm repair and, 598–
 603
 gut, 186
 myocardial, 339
 perioperative, cardiac mortality and, 519–520
 myocardial effects on, 486
 perioperative myocardial infarction and, 96–97
 ST depression-type, 90, 96–97
 ST elevation-type, 90
 stress-induced ST-depression-type, perioperative myocardial infar-
 ction and, 94
 ST segment depression-type, 92, 93
 ST segment elevation-type, 92, 93
- Ischemia-reperfusion, simulated, 488
- Ischemia-reperfusion injury, lung, theophylline added to modified
 Euro-Collins preservation solution and, 721–724
- Ischemic preconditioning, 459, 519–520
- Isoflurane
 left atrial function in dogs with pacing-induced cardiomyopathy and,
 709–714
 myocardial tissue oxygen pressure during canine coronary artery
 constriction and, 495–498
 one-lung ventilation and, 73–75

- Ketamine for pediatric cardiac catheterization
 advantages and disadvantages of, 688, 692
 propofol and, 691–693
 propofol *versus*, 683–684, 686–690
- Kinked triple-lumen central venous catheter due to superior vena caval
 cannula, 145–146
- Klippel-Feil syndrome, anesthetic challenges in patient with, 502–505
- Lactate
 myocardial, 598, 602–603
 differences before and after coronary artery bypass graft surgery
 in, prediction of pre- and postoperative functional state
 via, 478–485
 pyruvate *versus*, cardioprotection using, 715–720
- Laplace law, 660
- Laryngoscopy, coronary artery bypass graft surgery *versus* general
 surgery and, 321–324
- Leap Frog group recommendations, 564
- Length of stay, gender influence on, 346–351
- Lepirudin, 633
- Letters to the Editor
 anesthetic management of emergency Cesarean section and reopera-
 tive mitral valve replacement, 281–283
 atrial myxoma search and retrieval, transesophageal echocardi-
 ogram-assisted, 141–142
 double-lumen tube, accurate placement of, 781–782
 echocardiographic diagnosis of, 278–279
 facial nerve paralysis during cervical plexus block for carotid artery
 endarterectomy, 782–783
 fractured central venous catheter, 144–145
 height-based formula for double-lumen tracheal tube depth predic-
 tion, 412–413
 hemodynamic compromise after bougie placement, 782
 heparinase and thromboelastography to prevent excessive bleeding
 after coronary artery bypass graft surgery, 413–415
 nitric oxide as part of sweep gas infusion during cardiopulmonary
 bypass, 783–784
 pseudoaneurysm of subclavian artery after catheterization of subcla-
 vian vein, 143–144
 pulmonary artery catheter entrapment recognition with transesopha-
 geal echocardiography, 142–143
 thoracic epidural analgesia and coronary artery bypass grafting,
 677–678
 tracheal extubation, difficult, 279–280
 unexpected pressure waveform during pulmonary artery catheter
 placement, 678–679
 vancomycin interaction with Haemacel, 280–281
- Lidocaine, 358
- Lifepath endograft, 662
- Lipid peroxidation pathway, 723
- Liver, orthotopic transplantation of, adverse outcomes with, 699–702
- Lung
 high-frequency *versus* other ventilation methods during cardiopul-
 monary bypass and, 40–44
 ischemia-reperfusion injury of, theophylline added to modified Euro-
 Collins preservation solution and, 721–724
 one-, ventilation of (*See* Ventilation, one-lung)
 transfusion-related acute injury to, 122
 transplantation of (*See* Transplantation)
- Lung volume reduction surgery
 anesthetic management for, 359–360
 severe emphysema and, 366–370
- Mannitol, 17
- Mediastinum
 anterior mass of, 405–406
 frozen, aortic stenosis and, surgical approach for, 770–772
- Medtronic Freestyle valve, 241, 243
- Meperidine, thoracic epidural, arterial oxygenation during one-lung
 ventilation and, 302–305
- Midsternotomy, OPCAB surgery through, 86
- Miniroot inclusion technique, 243
- Minithoracotomy, conventional sternotomy *versus*, valve surgery and,
 325–328
- Moral hazard, 563
- Morphine, intrathecal, prolonged respiratory depression after, 230–231
- Multidrug-resistant organisms, 24–25
- Muscle rigidity, remifentanyl hydrochloride and, 66–67
- Myocardial infarction
 non-Q-wave, 90, 91
 clinical characteristics of patients with, 92
 pathophysiology of, 93
 prognosis after, 93
 ST depression- *versus* ST elevation-type, 93
 pathogenesis in nonsurgical patients of, 90–93
 perioperative, 96–98
 beta-blockers and, 95
 characteristics of, 90
 coronary thrombosis and, 95–96
 model of, 97–98
 mortality after, 90
 nonsurgical myocardial infarction *versus*, 93–96
 pathophysiology of, 90–100
 plaque rupture and, 95–96
 prolonged tachycardia and, 94–95
 stress-induced ST-depression-type ischemia and, 94
- Q wave, 90, 91
 lesions responsible for, 91
 non-Q-wave *versus*, 92
 timing of onset of, 91
- NASCET (North American Symptomatic Carotid Endarterectomy
 Trial), 10
- National Emphysema Treatment Trial (NETT), 368
- Neodymium:yttrium-aluminum-garnet laser, 642
- Neonate(s). *See also* Child(ren); Infant(s)
 transcutaneous carbon dioxide monitoring techniques in, 307
- Neurologic complications
 coronary artery bypass graft surgery *versus* off-pump coronary artery
 bypass graft surgery and, 260–261
 incidence after surgery of, 4–5
 nicotine effects after coronary artery bypass graft surgery on, 341–
 345
- Neuron-specific enolase (NSE), 1–3
 cerebral damage prediction with, 4–9, 598, 601–603
- Neuroprotection, thoracic aortic surgery and, retrograde cerebral per-
 fusion and, 768–769
- Nicardipine, myocardial diastolic function and, failed percutaneous
 transluminal coronary angioplasty and, 604–612
- Nicotine, neurocognitive decline after coronary artery bypass and,
 341–345
- Nifedipine, 95
- Nitinol U-Clip, 102–103, 111
- Nitric oxide, inhaled, pneumonectomy and, 394
- Nitroglycerin, myocardial diastolic function and, failed percutaneous
 transluminal coronary angioplasty and, 604–612
- Nonagenarian, anesthetic considerations for elective cardiac surgery in,
 647–654

- No-reflow phenomenon, 610
 Norepinephrine, 516
 North American Symptomatic Carotid Endarterectomy Trial (NASCET), 10
 Nosocomial infection(s), prevalence of, 23
- Obesity, difficult laryngoscopy in patients with, 323
 Occlusion device(s), atrial septal defect closure using, 755–763
 Octreotide, 132
 One-Shot Device, 103–105
 Oximetry sensors, near-infrared, 773–774
 Oxygen
 blood content of, hemoglobin levels and, 747
 100% during cardiopulmonary bypass and, 43
 pressure of, adenosine *versus* isoflurane *versus* desflurane effects on, canine coronary artery constriction and, 495–498
 reactive species of, 317
 Oxygenation
 one-lung ventilation and
 effects of desflurane, isoflurane, and propofol on, 73–75
 thoracic epidural meperidine and, 302–305
 regional venous, temperature and blood flow variation effects on, 182–187
- Parenchyma, lung, functional assessment of, 372
 Patent ductus arteriosus, other cardiac defects and, anesthetic management of patient with, 740–743
 Patent foramen ovale, 113, 116
 Percutaneous coronary intervention. *See* Angioplasty
 Percutaneous transluminal coronary angioplasty. *See* Angioplasty
 Perfusion
 cerebral, bispectral index to measure, cardiopulmonary resuscitation and, 506–508
 one-lung ventilation and, effects of desflurane, isoflurane, and propofol on, 73–75
 Photodynamic therapy, 643–644
 Plaque
 rupture of, 96–98
 perioperative myocardial infarction and, 95–96
 vulnerable, myocardial infarction and, 90–91
 Platelet count, heparin-coated extracorporeal circuits and, 165–170
 Pneumectomy
 dyspnea after, 131–133
 pulmonary edema after, 388–395
 Pneumonia
 incidence of, 24
 ventilator-associated (VAP), 22–27
 risk factors for, 23–27
 Positive end-expiratory pressure (PEEP), 364
 Preeclampsia, Cesarean section and, aortic dissection with, aprotinin during deep hypothermic circulatory arrest for, 252–257
 Preoperative autologous blood donation (PAD). *See* Blood, autologous, preoperative donation
 Propofol, 336, 339
 dexmedetomidine-based sedation regimens *versus* regimens based on, coronary artery bypass graft surgery and, 576–584
 laryngeal mask airway and, deep intravenous sedation with, transesophageal echocardiography and, 443–446
 one-lung ventilation and, 73–75
 pediatric cardiac catheterization and, 683–684, 689, 691–693
 thiopental *versus*, implantation of automatic internal cardioverter-defibrillator and, 613–616
 Protamine, pulmonary vasoconstriction and, 309–313
 Proteins, S-100, 1–3
- Pseudoaneurysm
 mitral-aortic intervalvular fibrosa, 668–671
 proximal aortic, 405–406
 Pulmonary function, central airway obstruction and, bronchoscopic procedures to relieve, 638–639
 Pump, intra-aortic balloon
 emergency use during off-pump coronary artery bypass graft surgery, factors leading to, 452–458
 placement via the ascending aorta of, intraoperative transesophageal echocardiographic imaging of, 736–739
 Pyruvate, cardioprotection using, cardiopulmonary bypass and, 715–720
- Regurgitation
 central aortic, 134–135
 tricuspid, severe, 233
 Relaxation, concentration-dependent, 466
 Remifentanyl
 alfentanil *versus*, effect on hemodynamic response during day-case rigid bronchoscopy of, 336–340
 thoracic epidural analgesia and, one-lung ventilation and, 69–71
 in vitro effect on isolated human right atria and saphenous veins of, 465–469
 Remifentanyl hydrochloride, 33–34, 38
 efficacy and safety of, 60–68
 hypertension and, 66–67
 hypotension and, 67–68
 muscle rigidity and, 66–67
 optimal dosing regimen of, 51–59
 adverse effects of, 58
 ICU recovery phase and, 55–56
 induction phase and, 52–55
 safety of, 56
 Renal dysfunction
 fenoldopam and, 17–21, 491–494
 incidence of, 17
 Respiration
 assessment of mechanical function of, 372
 depression of
 prolonged, intrathecal morphine and, 230–231
 propofol and, 576
 mechanical, severe emphysema and, 372
 Respiratory variation, positive-pressure ventilation, pericardial effusion and cardiac tamponade effects on, 45–50
 Respiratory weaning, 573–574
 Resuscitation, cardiopulmonary, adequate cerebral perfusion during, bispectral index as indicator of, 506–508
 Revascularization
 myocardial, procedure of choice for, 260–262
 transmyocardial, 258
 transmyocardial laser (TMLR), 400–402
 Ropivacaine, sufentanil with, 630
 Ross operation, 240
- S-100 β protein, 598, 601–603
 cerebral damage prediction with, 4–9
 SEN viruses, 122
 Sepsis, 122
 Sex. *See* Gender
 Shunt fraction, one-lung ventilation and, effects of desflurane, isoflurane, and propofol on, 73–75
 Smoking, cigarette, myocardial infarction and, 91
 SOS (Stent or Surgery Trial), 264
 Spinal cord, stimulants of, 258–259

- Spirometry, 372
- Splanchnic organs, acute normovolemic hemodilution and, 750
- S-100 proteins, 1–3, 4–9
- Stabilizer(s), 88
- STAR Flex occluder, 755–756
- ST depression-type ischemia. *See* Ischemia, ST depression-type
- Stenosis
 - carotid, endarterectomy for, perioperative mortality and morbidity with, 10–16
 - coronary, myocardial infarction and, 91
 - tricuspid, 233
- Stenting *vs.* Internal Mammary Artery study, 266
- Stent or Surgery Trial (SOS), 264
- Stent(s), airway, 641–642
- Sternotomy
 - median, severe post-operative pain with, management of, 359–360
 - minithoracotomy *versus*, valve surgery and, 325–328
- Steroid agents, ventilator-associated pneumonia and, 27
- Stress test
 - dipyridamole thallium, 703–708
 - preoperative, clinical predictors from the American College of Cardiology/American Heart Association Guidelines on Perioperative Evaluation before Noncardiac Surgery and, 694–698
- Stroke(s), 260
 - carotid endarterectomy for, 10
 - perioperative, cardiovascular aging and, 521
 - postsurgical incidence of, 4
- Stunning, myocardial, 609
 - triiodothyronine pretreatment effects on beta-adrenergic responses in, 486–490
- Succinylcholine, malignant hyperthermia development associated with, 625–628
- Symmetry Bypass Aortic Connector System, 101, 107
- Sympathetic nervous system, cardiovascular aging and, 516–517
- Tachycardia
 - prolonged, perioperative myocardial infarction and, 94–95
 - ventricular, dexmedetomidine and, 580–581
- Talent LPS stent graft, 662
- Tamponade, cardiac, respiratory variation and, 45–50
- Theophylline, modified Euro-Collins solution containing, hypothermic preservation of lung and, 721–724
- Thermodilution technique(s)
 - cardiac output monitoring with, 199–203
 - CardioQ output *versus*, off-pump coronary artery surgery and, 728–732
 - continuous pulmonary artery, continuous pulse contour analysis *versus*, 211–216
 - inert gas throughflow *versus*, cardiac output measurement using, 204–210
- Thiopental, propofol *versus*, implantation of automatic internal cardioverter-defibrillator and, 613–616
- Thoracotomy, -mini, conventional sternotomy *versus*, valve surgery and, 325–328
- Thrombin inhibitors, 171–175
- Thrombocytopenia, heparin-induced, bivalirudin for cardiopulmonary bypass in patient with, 632–635
- Thrombosis, 169
 - coronary, perioperative myocardial infarction and, 95–96, 96–98
- Thromboxane, 309
- Thrombus, right atrial, mental status changes due to, 509–511
- Timolol Multicenter Study, 95
- TMLR (transmyocardial laser revascularization), 400–402
- Toronto SPV valve, 243
- Trachea, intubation of, 291
- Tracheobronchial tree, adult cricoid ring diameter *versus*, double-lumen tube selection and, 299–301
- Tracheostomy, ventilator-associated pneumonia risks and, 27
- Transesophageal Doppler device(s), cardiac output measurement with, 217–220
- Transesophageal echocardiography (TEE), 214
 - American Society of Anesthesiologists and Society of Cardiovascular Anesthesiologists Task Force recommendations for, 117
 - color kinesis, 703–708
 - deep intravenous sedation with, propofol and laryngeal mask airway and, 443–446
 - Ebstein's anomaly and, 233, 234
 - epicardial and epiaortic echocardiography *versus*, 422–429
 - imaging of intra-aortic balloon placed via ascending aorta using, 736–739
 - left ventricular end-diastolic area measurement with, 188
 - left ventricular free wall rupture after minimally invasive mitral valve replacement and, 733–735
 - light sedation with, 443
 - malposition of venous cannula seen with, 269–170
 - observer variation in, 430–442
 - post aortic valve replacement, echolucent area identified by, 668–671
 - pulmonary artery catheter placement using, 129–130
 - stentless xenograft implantation assessment with, 247–249
 - unicuspid aortic valve diagnosis with, 82–83
 - ventricular assist device insertion and, 113–120
- Transfusion-related immune modulation (TRIM), 122
- Transfusion(s)
 - allogeneic, efficacy of acute normovolemic hemodilution in avoiding, 751
 - gender influence on utilization of, off-pump coronary artery bypass graft surgery and, 346–351
 - heparin-coated extracorporeal circuits and, 165–170
 - off-pump coronary artery bypass graft surgery and, with and without cardiopulmonary bypass during, 447–451
- Transient ischemic attack, 10
- Transmyocardial laser revascularization (TMLR), 400–402
- Transplantation, lung
 - early extubation and, 29–35
 - severe emphysema and, 370–371
 - single
 - early extubation after, 36–39
 - mode of transport of, 39
- Trendelenburg position, 456
- Triiodothyronine, pretreatment of stunned cardiac myocytes with, beta-adrenergic responses and, 486–490
- Troponin, 96–97
- Troponin-I, 94
- Tube(s)
 - double-lumen
 - endobronchial
 - adult cricoid ring *versus* main tracheobronchial tree diameter and, 299–301
 - cardiac output measurement using, 207
 - left-sided, 287–288, 289–298
 - complications with, 295
 - depth of, 291
 - hypoxemia during one-lung ventilation and, 294
 - positioning of, 291–292
 - confirmation of, 292–293

Tube(s) (*Continued*)

- ideal *versus* satisfactory, 293–294
- postoperative considerations with, 295
- right-sided *versus*, 289–290
- size of, 290–291
- tracheal intubation with, 291
- malpositioned, 636–637
- one-lung ventilation with, 355–356
- endobronchial blocker, 636–637
- endotracheal
 - double-lumen, 79
 - single-lumen with bronchial blocker *versus*, one-lung ventilation and, 725–727
 - one-lung ventilation with, 352–354
- Univent, 79, 352–354
- single-lumen with enclosed bronchial blocker, 636–637

UK Small Aneurysm Trial, 659

Univent tube, 79, 352–354, 636–637, 727

University of California, San Francisco, atrial septal occluder device experience at, 757

Vagal activity, cardiovascular aging and, 517

Valsalva maneuver, 509–511

Valve

- aortic
 - homograft regurgitation, 134–135
 - replacement of
 - echolucent area seen by transesophageal echocardiography after, 668–671
 - stentless xenografts for, 240–251
 - unicuspid, transesophageal echocardiographic diagnosis of, 82–83
- mitral
 - anterior, dissection and aneurysm of, transesophageal echocardiography diagnosis of, 271–272
 - malignant hyperthermia after cardiopulmonary bypass during surgery for replacement of, 625–628
 - minimally invasive replacement of, TEE localization of left ventricular free wall rupture after, 733–735
 - myxomatous mitral and tricuspid disease of, anesthetic challenges in cardiac surgery patient with Klippel-Feil syndrome and, 502–505
 - surgery on, minithoracotomy *versus* conventional sternotomy for, 325–328

VAP (ventilator-associated pneumonia), 22–27

Varapamil, 95

Vascular resistance, cardiovascular aging and, 516–517

Vasoconstriction, pulmonary, protamine-induced, central venous *versus* peripheral venous protamine infusion and, 309–313

VCS Autosuture Device, 106

Vein(s)

- saphenous, in vitro effect of remifentanyl and fentanyl on, 465–469
- stiffening of, 515

Ventilation

- adaptive support, fast-track surgery and, 571–575
- central airway obstruction relief and, 640
- lung, differential, bronchopleural fistula management using, 744–746
- mechanical
 - gender role in utilization of, off-pump coronary artery bypass graft surgery and, 346–351

Ventilation (*Continued*)

- prolonged, lung-transplant patients and, 31–32
- one-lung
 - arterial oxygenation during, thoracic epidural meperidine and, 302–305
 - double-lumen tubes for, left-sided, 289–298
 - effects of desflurane, isoflurane, and propofol during, 73–75
 - endobronchial blocker for
 - pediatric, 79–81
 - wire-guided, 352–354, 636–637
 - endotracheal tube for, double-lumen, single-lumen tube with bronchial blocker *versus*, 725–727
 - thoracic epidural analgesia with remifentanyl during, 69–71
 - tracheal diverticulum and, 355–356
 - transcutaneous *versus* end-tidal carbon dioxide techniques for, 306–308
 - positive-pressure, respiratory variation and, 45–50
- Ventilator, anesthetic induction using, severe emphysema and, 374–375
- Ventrica Magnetic Vascular Positioner, 107, 111
- Ventricle
 - left
 - abnormal wall motion of
 - definitions of, 706
 - quantitative analysis with color kinesis during aortic cross-clamping of, 703–708
 - apico-aortic valved conduit of, 770–772
 - free wall rupture of
 - echocardiographic localization after minimally invasive mitral valve replacement and, 733–735
 - risk factors for, 733–734
 - right
 - dysfunction of, post-lung resection, 378–379
 - rupture of, OPCAB surgery and, 87–89
- Ventricular assist device(s), transesophageal echocardiography during insertion of, 113–120
- Ventricular septal defect, 233
 - patent ductus arteriosus and right pulmonary artery hypoplasia and, anesthetic management of, 740–743
- Veterans Affairs Open Versus Endovascular Repair (OVER) Trial, 664
- Vitamin C, 317
- Vitamin E, 317
- Women. *See also* Gender
 - black, cerebrovascular morbidity and mortality post carotid endarterectomy and, 15
- Xenograft(s), stentless
 - advantages of, 240–242
 - background of, 240
 - Biocor SJM, 243
 - Cryolife-O'Brien, 243
 - echocardiographic assessment of, 247–249
 - Edwards Prima Plus, 243
 - homografts *versus*, 246–247
 - implantation technologies for, 242–243
 - Medtronic Freestyle, 241, 243
 - outcomes with, 243–245
 - stented *versus*, 246–247
 - Toronto SPV, 243
- Zenith endograft, 662